We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Waters' growth prospects are supported by sustained analytical sciences demand and BD integration.
WAT's Analytical Sciences revenues rose 9% in constant currency in Q2, supported by strong instrument demand.
Waters expects $50 million in revenue synergies and $75 million in cumulative cost savings from BD in 2026.
Waters (WAT - Free Report) is well-poised for growth in the coming quarters, driven by sustained demand for analytical sciences, an extended instrument replacement cycle, BD integration and synergies, product innovation and growing opportunities in bioseparations and AI-enabled pharmaceutical testing. However, weakness in China, uneven end-market recovery, reliance on customer capital spending and replacement-cycle trends remain key downsides.
Shares of this Zacks Rank #3 (Hold) company have gained 14.8% year to date against the industry's 6.2% decline. However, the S&P 500 Index has risen 14.5% in the said timeframe.
This renowned player offers analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies and has a market capitalization of $42.88 billion. WAT projects 10.9% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. The company’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 6.2%.
Image Source: Zacks Investment Research
Factors Favoring WAT Stock
Sustained Growth in Analytical Sciences: Waters continues to benefit from an extended instrument replacement cycle, improving pharmaceutical spending and demand for innovative analytical technologies. In the second quarter of 2026, Analytical Sciences revenues grew 9% in constant currency, supported by 8% growth in instruments, 10% in chemistry and 9% in services. Pharmaceutical and academic and government markets each grew 11%. Instrument revenues have grown at a CAGR of 2.5% since 2019, compared with the historical 5% rate, indicating further replacement opportunities. With high-single-digit organic growth for seven consecutive quarters, a replacement cycle expected through 2027 and about $100 billion in pharmaceutical reshoring investments planned from 2027 to 2030, Waters has multiple avenues to sustain growth.
BD Integration and Synergy Opportunities: Waters' acquisition of BD's Biosciences and Diagnostic Solutions businesses has expanded its presence in diagnostics, flow cytometry and recurring consumables. The acquired businesses generated $817 million in revenues in second-quarter 2026, reflecting 4% reported growth and 6% growth excluding China. Management's 180-day commercial improvement plan has delivered 90 basis points of pricing gains. WAT expects $50 million in revenue synergies and $75 million in cumulative cost savings in 2026. The company has advanced its cost-reduction initiatives, targeting $200 million in annualized savings by year-end, ahead of its three-year schedule. Management expects the acquired businesses to exit 2026 with growth of approximately 6% or better.
Innovation and Expanding Product Opportunities: Waters' product innovation strategy is strengthening its competitive position. The recent launch of the BD FACSDiscover A7 Cell Analyzer expands its spectral flow cytometry portfolio, while the BACTEC FXI blood culture system offers a multiyear replacement opportunity, with more than 12,000 aging instruments globally. In Analytical Sciences, the Xevo MRT P10 and Xevo TQ Absolute XR support demand across multi-omics, pharmaceutical testing and PFAS analysis. Growing demand for bioseparations products in GLP-1 and biologics applications, and early adoption of AI in pharmaceutical quality control, are contributing to additional software licenses and consumables demand. These developments could extend the company's growth opportunities beyond instrument replacements.
Factors That May Offset WAT's Gains
Weakness in China Diagnostics and Biosciences: China continues to constrain growth in WAT’s acquired Biosciences and Diagnostic Solutions operations. In the second quarter, Biosciences growth faced a two-percentage-point drag from China, while Flow Clinical revenues in the country declined 20% amid diagnosis-related group reimbursement restrictions and limited local product availability. The microbiology business reported a 13% revenue decline in China. Waters is pursuing export approvals, localized flow cytometry offerings and commercial improvements, but recovery depends on execution and the rollout of revised reimbursement policies across provinces. Prolonged weakness could limit growth in the acquired businesses.
BD Integration Execution Risk: The integration of the acquired BD businesses remains a major execution undertaking because Waters is carving operations out of a large parent rather than completing a conventional integration. Management has acknowledged strain on internal systems and processes as Waters absorbs a business of comparable scale while still relying on transitional services. Delays in localization, commercial execution, cross-selling or cost initiatives could postpone the anticipated benefits. Management also plans to reinvest part of the savings into growth initiatives, which could moderate the pace of near-term margin expansion.
Uneven End-Market Recovery and Replacement-Cycle Dependence: Waters remains partly dependent on customer capital spending and the continuation of its replacement cycle. Although pharmaceutical demand has recovered, certain end markets continue to exhibit uneven spending patterns. In the second quarter of 2026, the Analytical Sciences industrial end market grew only 1%, with weakness in chemical analysis partially offsetting demand for PFAS testing. Academic and government demand has also remained sensitive to funding availability, particularly in China. While management expects instrument replacements to continue through 2027, the pace of demand beyond that remains less certain. Delays in pharmaceutical reshoring projects or renewed spending caution could also temper growth momentum.
Waters has been witnessing a stable estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has remained unchanged at $14.56.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $1.75 billion and $3.99, suggesting 119.3% and 17.4% growth, respectively, from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical Services (WST - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Key Takeaways
Waters (WAT - Free Report) is well-poised for growth in the coming quarters, driven by sustained demand for analytical sciences, an extended instrument replacement cycle, BD integration and synergies, product innovation and growing opportunities in bioseparations and AI-enabled pharmaceutical testing. However, weakness in China, uneven end-market recovery, reliance on customer capital spending and replacement-cycle trends remain key downsides.
Shares of this Zacks Rank #3 (Hold) company have gained 14.8% year to date against the industry's 6.2% decline. However, the S&P 500 Index has risen 14.5% in the said timeframe.
This renowned player offers analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies and has a market capitalization of $42.88 billion. WAT projects 10.9% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. The company’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 6.2%.
Image Source: Zacks Investment Research
Factors Favoring WAT Stock
Sustained Growth in Analytical Sciences: Waters continues to benefit from an extended instrument replacement cycle, improving pharmaceutical spending and demand for innovative analytical technologies. In the second quarter of 2026, Analytical Sciences revenues grew 9% in constant currency, supported by 8% growth in instruments, 10% in chemistry and 9% in services. Pharmaceutical and academic and government markets each grew 11%. Instrument revenues have grown at a CAGR of 2.5% since 2019, compared with the historical 5% rate, indicating further replacement opportunities. With high-single-digit organic growth for seven consecutive quarters, a replacement cycle expected through 2027 and about $100 billion in pharmaceutical reshoring investments planned from 2027 to 2030, Waters has multiple avenues to sustain growth.
BD Integration and Synergy Opportunities: Waters' acquisition of BD's Biosciences and Diagnostic Solutions businesses has expanded its presence in diagnostics, flow cytometry and recurring consumables. The acquired businesses generated $817 million in revenues in second-quarter 2026, reflecting 4% reported growth and 6% growth excluding China. Management's 180-day commercial improvement plan has delivered 90 basis points of pricing gains. WAT expects $50 million in revenue synergies and $75 million in cumulative cost savings in 2026. The company has advanced its cost-reduction initiatives, targeting $200 million in annualized savings by year-end, ahead of its three-year schedule. Management expects the acquired businesses to exit 2026 with growth of approximately 6% or better.
Innovation and Expanding Product Opportunities: Waters' product innovation strategy is strengthening its competitive position. The recent launch of the BD FACSDiscover A7 Cell Analyzer expands its spectral flow cytometry portfolio, while the BACTEC FXI blood culture system offers a multiyear replacement opportunity, with more than 12,000 aging instruments globally. In Analytical Sciences, the Xevo MRT P10 and Xevo TQ Absolute XR support demand across multi-omics, pharmaceutical testing and PFAS analysis. Growing demand for bioseparations products in GLP-1 and biologics applications, and early adoption of AI in pharmaceutical quality control, are contributing to additional software licenses and consumables demand. These developments could extend the company's growth opportunities beyond instrument replacements.
Factors That May Offset WAT's Gains
Weakness in China Diagnostics and Biosciences: China continues to constrain growth in WAT’s acquired Biosciences and Diagnostic Solutions operations. In the second quarter, Biosciences growth faced a two-percentage-point drag from China, while Flow Clinical revenues in the country declined 20% amid diagnosis-related group reimbursement restrictions and limited local product availability. The microbiology business reported a 13% revenue decline in China. Waters is pursuing export approvals, localized flow cytometry offerings and commercial improvements, but recovery depends on execution and the rollout of revised reimbursement policies across provinces. Prolonged weakness could limit growth in the acquired businesses.
BD Integration Execution Risk: The integration of the acquired BD businesses remains a major execution undertaking because Waters is carving operations out of a large parent rather than completing a conventional integration. Management has acknowledged strain on internal systems and processes as Waters absorbs a business of comparable scale while still relying on transitional services. Delays in localization, commercial execution, cross-selling or cost initiatives could postpone the anticipated benefits. Management also plans to reinvest part of the savings into growth initiatives, which could moderate the pace of near-term margin expansion.
Uneven End-Market Recovery and Replacement-Cycle Dependence: Waters remains partly dependent on customer capital spending and the continuation of its replacement cycle. Although pharmaceutical demand has recovered, certain end markets continue to exhibit uneven spending patterns. In the second quarter of 2026, the Analytical Sciences industrial end market grew only 1%, with weakness in chemical analysis partially offsetting demand for PFAS testing. Academic and government demand has also remained sensitive to funding availability, particularly in China. While management expects instrument replacements to continue through 2027, the pace of demand beyond that remains less certain. Delays in pharmaceutical reshoring projects or renewed spending caution could also temper growth momentum.
Waters Corporation Price
Waters Corporation price | Waters Corporation Quote
Estimate Trend
Waters has been witnessing a stable estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has remained unchanged at $14.56.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $1.75 billion and $3.99, suggesting 119.3% and 17.4% growth, respectively, from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical Services (WST - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.